Zepbound, originally approved for obesity with tirzepatide, has shown promise in treating obstructive sleep apnea. Early studies reveal improved outcomes in patient trials, encouraging further FDA evaluation.
Obstructive sleep apnea affects 100 million globally, causing sleep interruptions due to breathing cessation. Zepbound's potential expansion to treat this condition can bring positive health outcomes and reduce risks of heart diseases.
[
add
]
[
|
|
...
]